INTROGEN REPORTS RESULTS OF INGN 225 TRIAL

Introgen Therapeutics has reported the publication of data from a Phase I/II clinical study of INGN 225 in patients with advanced lung cancer. INGN 225 is an investigational p53 based immunotherapy. The data appear in the journal Clinical Cancer Research.

Following INGN 225 treatment and chemotherapy, 62 percent of evaluable patients demonstrated objective tumor responses. Historically, response rates to second line chemotherapy in this disease range from only 5 percent to 25 percent. Similar patients with this type of lung cancer have a poor prognosis and most live less than six months, but patients on this study survived for almost 12 months.